On-demand treatment of hereditary angioedema attacks: Patient-reported utilization, barriers, and outcomes

Hereditary angioedema (HAE) is clinically characterized by recurrent attacks of subcutaneous and submucosal swelling. To investigate real-world timing, potential barriers, and impact of delaying on-demand treatment (OD) of HAE attacks. Patients with HAE (type I or II) aged 12 years or older with more than or equal to 1 treated (Treated Cohort) or untreated (Untreated Cohort) attack in the past 3 months were recruited by the US HAE Association. Respondents completed a 20-minute, self-reported, online survey about their last HAE attack. In the Treated Cohort (n = 94), of the 67% who reported treating their attack early, only 26% administered OD in less than 1 hour. Furthermore, 79% (n = 74) reported treatment-related anxiety, which correlated with treatment delay. Time to treatment paralleled changes in attack severity (33% mild attacks treated in